Ethylene

Ethylene

SCHEMBL6036892

C=C.O=C1CCC(O)(c2ccc(F)cc2)CC1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.46
OPRK1 P41145 3/20 0.46
OPRD1 P41143 2/20 0.46
OPRL1 P41146 2/20 0.46
TSHR P16473 2/20 0.42
DRD2 P14416 8/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.39
DRD3 P35462 3/20 0.38
DRD4 P21917 2/20 0.38
CCR1 P32246 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
HTR1A P08908 2/20 0.37
ADRA2A P08913 2/20 0.37
CYP2D6 P10635 2/20 0.37
CHRM1 P11229 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
CHRM3 P20309 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613615 0.96 OPRM1 (0.45) OPRM1OPRK1OPRD1OPRL1TSHR
Ethylene SCHEMBL8880978 0.81 OPRM1 (0.46) OPRM1OPRK1OPRD1OPRL1DRD2
Ethylene SCHEMBL16040738 0.81 OPRM1 (0.34) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL7824744 0.80 OPRM1 (0.53) OPRM1OPRK1OPRD1OPRL1TSHR
SCHEMBL612855 0.79 ESR2 (0.43) DRD2DRD3DRD4CYP1A2CYP3A4
Ethylene SCHEMBL3235445 0.78 CYP19A1 (0.37) OPRM1OPRK1OPRD1OPRL1CYP3A4
SCHEMBL743825 0.77 KMT2A (0.39) OPRM1OPRK1OPRL1DRD2DRD3
SCHEMBL613284 0.77 OPRM1 (0.49) OPRM1OPRK1OPRD1OPRL1DRD2
SCHEMBL613957 0.77 DRD2 (0.58) OPRM1OPRK1OPRD1OPRL1TSHR
SCHEMBL15349268 0.77 OPRM1 (0.45) OPRM1OPRK1OPRD1OPRL1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414813-B1 1,2,4-TRIOXOLANE ANTIMALARIALS MEDICINES MALARIA VENTURE MMV (CH) 2006-09-13 EP disclosed
US-6906205-B2 Spiro and dispiro 1,2,4-trioxolane antimalarials MEDICINES FOR MALARIA VENTURE MMV (CH) 2005-06-14 US disclosed
US-6828341-B2 Brain disorders; anticonvulsants; central nervous system disorders; psychological disorders WARNER-LAMBERT COMPANY 2004-12-07 US disclosed
US-20040186168-A1 Such as spiroadamantane on one side and 4-substituted spiro-cyclohexyl on other side; structurally simple, nontoxic, easy synthesis, potent parasiticides MEDICINES FOR MALARIA VENTURE MMV (CH) 2004-09-23 US disclosed
EP-1414813-A1 1,2,4-TRIOXOLANE ANTIMALARIALS Medicines for Malaria Venture (CH) 2004-05-06 EP disclosed
WO-2003000676-A1 1,2,4-TRIOXOLANE ANTIMALARIALS MEDICINES FOR MALARIA VENTURE (CH) 2003-01-03 WO disclosed
US-20030004212-A1 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists DEORAZIO RUSSELL JOSEPH (US) 2003-01-02 US disclosed
US-6486199-B1 Spiro and dispiro 1,2,4-trioxolane antimalarials MEDICINES FOR MALARIA VENTURE MMV INTERNATIONAL CENTRE COINTRIN (CH) 2002-11-26 US disclosed
EP-1251128-A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists WARNER-LAMBERT COMPANY (US) 2002-10-23 EP disclosed
US-5643904-A Substituted hexahdryoazepinones and tetrahydrobenzazepinones PFIZER INC. (US) 1997-07-01 US disclosed
US-5484917-A FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS, PAIN AND ANXIETY PFIZER INC. (US) 1996-01-16 US disclosed
EP-0625145-A1 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS PFIZER INC. (US) 1994-11-23 EP disclosed
WO-1993015059-A1 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS PFIZER INC. (US) 1993-08-05 WO disclosed
CN-1074903-A The six hydrogen azepine  ketone and the tetrahydro benzo azepine  ketone that replace PFIZER (US) 1993-08-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004212-A1 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists GLRB, GRIN1, GRIN2B OPRM1 4/4885OPRK1 6/4885OPRD1 5/4885
US-20040186168-A1 Such as spiroadamantane on one side and 4-substituted spiro-cyclohexyl on other side; structurally simple, nontoxic, easy synthesis, potent parasiticides DHODH, SQLE, SULT1E1 OPRM1 1933/4885OPRK1 1623/4885OPRD1 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.